Genentech Faces Arbitration Over Cancer Drug Licensing

Law360, New York (June 11, 2013, 6:34 PM EDT) -- PDL BioPharma Inc. said Tuesday that it had hit Genentech Inc. with an arbitration action in New Jersey for allegedly underpaying pharmaceutical royalties on license agreements related to cancer drugs and possibly other products.

The notice of arbitration that Nevada-based PDL lodged with the American Arbitration Association in Voorhees, N.J., also accuses the Hoffmann-La Roche Inc. unit of impeding PDL's efforts to have Genentech's books and records inspected to determine the accuracy of past royalty payments. Based on its rights under license agreements, PDL tapped KPMG...
To view the full article, register now.